Tumor Ablation Market Size, Share & Trends Report

Tumor Ablation Market Size, Share & Trends Analysis Report By Technology (Radiofrequency, Microwave), By Treatment (Surgical, Laparoscopic, Percutaneous) By Application, By Region, And Segment Forecasts, 2020 - 2027

  • Published Date: Feb, 2020
  • Base Year for Estimate: 2019
  • Report ID: 978-1-68038-746-9
  • Format: Electronic (PDF)
  • Historical Data: 2016 - 2018
  • Number of Pages: 120

Report Overview

The global tumor ablation market size was valued at USD 1.1 billion in 2019 and is anticipated to witness a CAGR of 11.2% over the forecast period. The rising prevalence of cancer and the high demand for safer therapeutic options are major factors contributing to the growth of the market. According to the WHO, it is projected that around 10 to 11 million cancer cases will be diagnosed each year globally, till 2030. The number of new cancer cases is expected to increase by more than 80% in low-income countries compared to half the rate in high-income countries (40%) from 2008 to 2030. Lucrative growth potential in currently available therapeutic options, and high demand for minimally and non-invasive therapies are the factors expected to drive the market in upcoming years.

Japan tumor ablation market size

The increasing inclination of surgeons and patients towards minimally invasive procedures owing to the benefits such as speedy recovery, patient comfort, and reduced turnaround time are the factors expected to drive the demand for advanced tumor ablation techniques over the forecast period. Advanced tumor ablation procedures are generally performed on an outpatient basis and do not require any hospital admission compared with conventional therapies, thereby significantly reducing the total healthcare cost.

According to a report by the Our World in Data (OWD), a project by Global Change Data Lab, over 70% of cancer cases occurred in people aged (50-older) in 2017. The number is expected to increase proportionally with the rising geriatric population. The aging population comprises of the main target population for noninvasive ablation techniques as the body’s biological functions get compromised during normal aging. Therefore, the rapidly increasing aging population is expected to boost the demand for tumor ablation techniques during the forecast period. 

Technological advancements to enhance accuracy, portability, and cost-effectiveness are the factors prompting market players to constantly improve and launch advanced devices. Image-guided equipment and cryoablation are major examples of these technological advancements. Usage of cooled radiofrequency denervation technique with internally cooled radiofrequency probes to enlarge the size of the lesion is one of the emerging techniques which is anticipated to play a significant role in market expansion. This technique enables complete denervation of the sacroiliac joint which helps in pain management.

Technology Insights

Based on technology, the market is segmented into the microwave, radiofrequency, cryoablation, and others. The others segment includes technologies such as radioiodine and laser ablation. The radiofrequency tumor ablation technology segment held a substantial share in 2019. The dominance can be attributed to its advantages such as specificity and efficiency in solid tumor ablation procedures in the kidney and liver. Additionally, radiofrequency ablation can be used to treat multiple tumors at the same time, thus improving procedural efficiency with the use of multiple electrodes placed at different sites. This is expected to boost the adoption rate of advanced tumor ablation techniques.

The success rate of radiofrequency/microwave ablation technology in eliminating small liver tumors is estimated to be greater than 85%. According to the NCBI report, the recurrence of tumors in patients opting for surgical resection ranged from 30% to 70%. On the other hand, tumor recurrence is very low (0.7-8%) in cases of radiofrequency ablation for similar tumors. The advantages of radiofrequency techniques to successfully treat tumors at early stages are expected to drive the tumor ablation market growth during the forecast period.     

Microwave ablation technology is anticipated to witness a remunerative market growth over the forecast period. The energy of the microwave (MW) ablation device is a propagating electromagnetic field, unlike the electric current in a radiofrequency ablation device. This improves the application of microwave ablation technology in tissue with low electrical conductance such as bones and lungs. The major benefits of this technology include larger tumor ablation volume, consistency in high temperature, low ablation pain, and optimal heating of the cystic mass. These benefits are anticipated to support the growth of this segment. Furthermore, minimum procedure time (5-10 minutes), improved efficacy with minimal complications, and reduced hospital stay are expected to drive the segment growth.

Treatment Insights

Based on treatment, the tumor ablation market is segmented into surgical procedures, laparoscopic procedures, and percutaneous procedures. The surgical ablation segment held a substantial share of in 2019, increased prevalence of liver and breast cancer, and unavailability of advanced tumor ablation techniques for these particular organs are the factors estimated to fuel the segment growth.

Global tumor ablation market share

The percutaneous ablation segment is expected to exhibit lucrative growth over the forecast period. These procedures offer faster recovery, minimal scarring, and increased safety. In addition, factors such as quick surgery time, patient comfort, and cost-efficiency are anticipated to further boost the segment demand. However, higher complications associated with the system are anticipated to limit its growth especially in the hospitals lacking skilled professionals.

According to the NCBI report, percutaneous ablations are not feasible in about 25-55% of patients due to unfavorable tumor locations. The tumor recurrence rate is higher in percutaneous ablation, due to insufficient ablation of the tumors located deep inside the tissue. Additionally, percutaneous ablation is contraindicated in treating lesions that are very adjacent to the gastrointestinal tract, gall bladder, bile duct, and heart due to the high risk of tumor recurrence. Therefore, in such a case, laparoscopic ablation is efficient in providing long term outcomes with simultaneously retaining minimal invasiveness. This is expected to boost the laparoscopic ablation segment growth during the forecast period.

Application insights

On the basis of application, the market is segmented into kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer, and others. Other segment includes various types of cancer such as bone metastasis and ENT cancer. The availability of advanced methods and increasing cancer prevalence are anticipated to facilitate market growth. Liver cancer dominates the market shares in 2019, accounting for nearly 19.83% of the market. This can be attributed to the rising incidence of bile duct cancer as well as primary liver cancer.

Renal cancer is anticipated to experience the fastest growth during the forecast period. Radiofrequency and microwave ablation technology are effective in the treatment of renal tumors. Patients having solitary kidney, tumor size (less than 4cm), and the slow post-surgical recovery rate are prospects for the ablation of kidney tumors. According to the American Cancer Society, in 2019, the number of new cases diagnosed with renal cancer was 73,820. Additionally, with the increasing use of medical imaging, the number of diagnosed cases is expected to increase driving the demand for treatment procedures during the forecast period.   

The lung cancer application segment is anticipated to grow at a rapid pace during the forecast period. This can be attributed to the increasing incidence of the disease. For instance, in 2018, lung cancer accounted for nearly 11.6% of total new cancer cases across the globe, meanwhile, Non-Small Cell Lung Cancer (NSCLC) accounted for 85% of all lung cancer cases. Radiofrequency ablation is widely used for the treatment of NSCL and is thereby anticipated to propel the market growth.

Regional Insights

North America dominated the overall market in 2019. Major factors contributing to the growth of this region include government support for quality healthcare, high purchasing power parity, availability of reimbursements, and increasing prevalence of cancer. For instance, in the U.S., the Patient Protection and Affordable Care Act (PPACA), promotes the quality and affordability of health care through health coverage policies to reduce the cost of healthcare for individuals and the government. In addition, the precision medicine initiative in formulating tailored strategies on unique characteristics of diseases. Hence, such government initiatives are anticipated to improve the overall healthcare system, thus boosting the market growth.

Europe followed North America is dominating the market in 2019. A greater extent of public funding in Europe’s healthcare system has contributed to this growth. Moreover, the growing geriatric population coupled with government support to control cancer is estimated to boost the market growth in this region. For instance, the European Cancer Observatory aims to create awareness about cancer, early diagnostic techniques, and advanced, minimally invasive therapeutic options.

The Asia Pacific is expected to register the fastest growth rate during the forecast period. The expanding patient population and the growing presence of major healthcare providers in rapidly developing economies such as India and China open growth opportunities. In addition, with government assistance, healthcare utilization in the Asia Pacific is improving. For instance, the Indian government provides financial assistance for poor patients suffering from cancer under the Health Minister Cancer Patient Fund (HMCPF) scheme.  This is anticipated to fuel the demand for tumor ablation devices growth of this region over the forecast period.

Tumor Ablation Market Share Insights

Key players of this market are Galil Medical Inc.; Misonix Inc.; HealthTronics; Angiodynamics (Covidien); Boston Scientific Corporation; Medtronic Plc.; SonaCare Medical; EDAP TMS S.A.; and Neuwave Medical Inc. These industry players have adopted various strategies to sustain their position in the market. For instance, new product launches, collaborations, technological advancements, mergers, and acquisitions are the key strategic initiatives in this industry. Galil Medical Inc. launched a new family of cryoablation needles, IcePearl 2.1 CX and IceFORCE 2.1CX. The launch of these products is expected to strengthen the company’s product portfolio. Houston Methodist Hospital acquired EDAP's Focal One system in early 2019. This acquisition is based on the positive experience of the hospital post the acquisition of EDAP's Ablatherm system in 2016. Senior Vice President of Operations at the hospital stated that acquiring EDAP's technology not only benefits patients but also hospital financials.

Report Scope



Base year for estimation


Actual estimates/Historical data

2016 - 2018

Forecast period

2020 - 2027

Market representation 

Volume in ‘000 units, revenue in USD Million, and CAGR from 2020 to 2027

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Country scope

U.S., Canada, U.K., Germany, France, Italy, Spain, Russia, Netherland, Switzerland, Belgium, Hungary, China, India, Japan, Thailand, South Korea, Taiwan, Singapore, Malaysia, Indonesia, Philippines, Mexico, Brazil, Colombia, Argentina, Chile, South Africa, Saudi Arabia, UAE, Turkey, Israel

Report coverage         

Revenue forecast, company share, competitive landscape, growth factors, and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global tumor ablation market report on the basis of technology, treatment, application, and region:

  • Technology Outlook (Volume, ‘000 Units; Revenue, USD Million, 2016 - 2027)

    • Radiofrequency ablation

    • Microwave ablation

    • Cryoablation

    • Irreversible electroporation ablation

    • Other ablation technologies

  • Treatment Outlook (Volume, ‘000 Units; Revenue, USD Million, 2016 - 2027)

    • Surgical ablation

      • Kidney cancer

      • Liver cancer

      • Breast cancer

      • Lung cancer

      • Prostate cancer

      • Other cancer

    • Laparoscopic ablation

      • Kidney cancer

      • Liver cancer

      • Breast cancer

      • Lung cancer

      • Prostate cancer

      • Other cancer

    • Percutaneous ablation

      • Kidney cancer

      • Liver cancer

      • Breast cancer

      • Lung cancer

      • Prostate cancer

      • Other cancer

  • Application Outlook (Revenue, USD Million, 2016 - 2027)

    • Kidney cancer

    • Liver cancer

    • Breast cancer

    • Lung cancer

    • Prostate cancer

    • Other cancer

  • Regional Outlook (Revenue, USD Million, 2016 - 2027)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

      • France

      • Italy

      • Spain

      • Russia

      • Netherland

      • Switzerland

      • Belgium

      • Hungary

    • Asia Pacific

      • China

      • Japan

      • India

      • Thailand

      • South Korea

      • Taiwan

      • Malaysia

      • Singapore

      • Indonesia

      • Philippines

    • Latin America

      • Brazil

      • Mexico

      • Argentina

      • Colombia

      • Chile

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

      • Turkey

      • Israel

Pricing & Purchase Options

Service Guarantee

  • Insured Buying

    This report has a service guarantee. We stand by our report quality.

  • Confidentiality

    We are in compliance with GDPR & CCPR norms. All interactions are confidential.

  • Custom research service

    Design an exclusive study to serve your research needs.

  • 24/5 Research support

    Get your queries resolved from an industry expert.

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities